<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A reliable focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> model is essential in evaluating the efficacy and safety of neuroprotective therapy for <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>We present a focal embolic ischemic model of rat with reproducible and predictable <z:e sem="disease" ids="C0751955" disease_type="Disease or Syndrome" abbrv="">brain infarction</z:e> by comparing it with two other most commonly used focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> models </plain></SENT>
<SENT sid="2" pm="."><plain>To produce embolic focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>, 30 male Wistar rats were subjected to injection of 30 microl hydrophilic polyvinylsiloxane (PVS) or an autologous <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> or intraluminal filament occlusion in the right middle cerebral artery (<z:chebi fb="70" ids="34342">MCA</z:chebi>) (n = 10 in each group) </plain></SENT>
<SENT sid="3" pm="."><plain>The percent of brain <z:mpath ids='MPATH_124'>infarct</z:mpath> volume at 48 h after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, neurobehavioral score at 2 h before and after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, intracranial hemorrhagic incidence, and premature reperfusion rate at 3 h after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> by <z:chebi fb="70" ids="34342">MCA</z:chebi> angiography were assessed respectively and compared between the focal cerebral models </plain></SENT>
<SENT sid="4" pm="."><plain>We found that PVS-induced focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> had more consistent brain <z:mpath ids='MPATH_124'>infarct</z:mpath> size with less dispersion (32.2+/-7.4%, CV = 0.23) than that with an intraluminal filament occlusion (27.6+/-11.4%, CV = 0.41) or an autologous <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> embolization (27.2+/-11.8%, CV = 0.43) </plain></SENT>
<SENT sid="5" pm="."><plain>Injection of PVS also caused more severe neurobehavioral deterioration (3.8+/-0.4) than those produced by two other models (filament, 3.1+/-0.9, P = 0.02; thrombotic, 3.5+/-0.5, P = 0.08) </plain></SENT>
<SENT sid="6" pm="."><plain>Additionally, animals with PVS-induced focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> suffered less <z:hpo ids='HP_0002170'>intracranial hemorrhage</z:hpo> (PVS, 0/10, filament, 3/10, thrombotic, 3/10), and less premature reperfusion as determined by <z:chebi fb="70" ids="34342">MCA</z:chebi> angiography (PVS, 0/10, filament, 4/10, thrombotic, 3/10) </plain></SENT>
<SENT sid="7" pm="."><plain>Our data suggests that permanent focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> with high reproducibility and low mortality can be achieved by introducing PVS into the right <z:chebi fb="70" ids="34342">MCA</z:chebi> </plain></SENT>
</text></document>